There is an ever-increasing pressure to reduce costs in a challenged economy. However, a sole focus on the cost of dressings without thought for the total cost for a care ‘episode’ could represent a false economy, failing to consider long-term patient outcomes. Advanced wound dressings can help manage the wound environment, improve healing rates, reduce healing time and long-term disabling outcomes and, therefore, minimise the costs associated with care. This International Making the Case explores PROMOGRAN and PROMOGRAN PRISMA in this context.
Supported by Systagenix, An Acelity Company